Terns Pharma announces positive Phase IIa top-line NASH data

9 August 2023

Sino-American biotech Terns Pharmaceuticals (Nasdaq: TERN) yesterday revealed positive top-line results from the Phase IIa DUET clinical trial of TERN-501, both alone and in combination with TERN-101, for the treatment of non-alcoholic steatohepatitis (NASH).

There are no Food and Drug Administration (FDA)-approved therapies, but the NASH market holds enormous untapped potential, and it is estimated to be worth as much as $27 billion by the end of the decade.

TERN-501 is an orally administered thyroid hormone receptor-beta (THR-β) agonist and TERN-101 is a liver-distributed farnesoid X receptor (FXR) agonist, both in development to treat NASH.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK